Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Current Assets (2016 - 2025)

Lipocine (LPCN) has disclosed Current Assets for 13 consecutive years, with $15.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Assets fell 22.31% year-over-year to $15.9 million, compared with a TTM value of $15.9 million through Sep 2025, down 22.31%, and an annual FY2024 reading of $22.3 million, down 2.36% over the prior year.
  • Current Assets was $15.9 million for Q3 2025 at Lipocine, down from $18.4 million in the prior quarter.
  • Across five years, Current Assets topped out at $47.2 million in Q2 2021 and bottomed at $15.9 million in Q3 2025.
  • Average Current Assets over 5 years is $30.7 million, with a median of $27.1 million recorded in 2023.
  • The sharpest move saw Current Assets soared 119.14% in 2021, then plummeted 33.03% in 2023.
  • Year by year, Current Assets stood at $46.4 million in 2021, then fell by 26.4% to $34.1 million in 2022, then tumbled by 33.03% to $22.9 million in 2023, then decreased by 2.36% to $22.3 million in 2024, then fell by 28.63% to $15.9 million in 2025.
  • Business Quant data shows Current Assets for LPCN at $15.9 million in Q3 2025, $18.4 million in Q2 2025, and $20.3 million in Q1 2025.